Drugs / Vγ9Vδ2 T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06396481 | Apr 2024 → Dec 2026 expected | diffuse intrinsic pontine glioma, glioblastoma, medulloblastoma | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vγ9Vδ2 T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06396481 ↗ |
| Modality | Cell therapy | “Making it one of the most promising cell therapies.” NCT06396481 ↗ |
| Route | Other | “Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week” NCT06396481 ↗ |